A Product and Pipeline Analysis of the Global Knee Cartilage Repair Market

A Product and Pipeline Analysis of the Global Knee Cartilage Repair Market

A New Standard of Care May be on the Horizon

RELEASE DATE
19-Sep-2014
REGION
North America
Research Code: NE07-01-00-00-00
SKU: LS00127-NA-MR_16968
AvailableYesPDF Download

$5,000.00

Special Price $3,750.00 save 25 %

In stock
SKU
LS00127-NA-MR_16968

$5,000.00

$3,750.00save 25 %

DownloadLink
ENQUIRE NOW

Description

The standard of care, microfracture, does not fulfill long-term needs for patients with chondral defects. In addition, current alternative treatment options are plagued by multiple challenges and limitations. This research service focuses on medicine in the knee cartilage repair market, providing a detailed overview of 9 key products. A product and pipeline assessment is provided for marketed and investigational autologous cell-based therapy, allogenic cell-based therapy, and non-cellular products in the global, US, and European markets. Product profiles are included for companies that are currently or imminently marketing cell-based regenerative therapies and conducting clinical trials in the United States and Europe.

Table of Contents

Key Findings

Key Findings (continued)

The Ideal Knee Chondral Defect Repair Solution

Key Companies to Watch

Other Companies to Watch

Market Definitions

Market Opportunity

Market Overview

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Market Overview (continued)

Current Cartilage Treatment Options

Significant Unmet Need Continues to Exist for Patients with Grades 3 and 4 Knee Chondral Defects

Technology Improvement Increases Product Utility

Market Drivers and Restraints

Recent Market Developments

Recent Market Developments (continued)

Knee Cartilage Repair Market—Competitive Landscape of Key Products

Knee Cartilage Repair Market—Competitive Landscape of Key Products (continued)

Differentiators for Key Marketed and Pipeline Products

Differentiators for Key Marketed and Pipeline Products (continued)

Differentiators for Key Marketed and Pipeline Products (continued)

Competitive Landscape—Pivotal Phase 3 Trials for Key Products

Competitive Landscape—Post-marketed Trials for Key Products

Global Estimated Approval Timelines for Key Products

Regulatory Pathway for Key Products

Knee Cartilage Repair Market—US Competitive Landscape of all Marketed and Pipeline Products

Marketed Product Analysis of Key Products—US

Pipeline Analysis of Key Products—US

US Competitive Landscape—Pivotal Phase 3 Trials

US Pivotal Phase 3 Trial Details

US Competitive Landscape—Post-marketed Trials

Knee Cartilage Repair Market—Europe Competitive Landscape of all Marketed Products

Knee Cartilage Repair Market—Europe Competitive Landscape of all Pipeline Products

Key Marketed Product Analysis—Europe

Key Marketed Product Analysis—Europe (continued)

Key Product Pipeline Analysis—Europe

Europe Competitive Landscape—Pivotal Phase 3 Trials

Europe Pivotal Phase 3 Trials

Europe Pivotal Phase 3 Trials (continued)

Europe Estimated Approval Timelines

NeoCart—Timelines for Focal Cartilage Defects

NeoCart—Clinical Trial Design Approach and Key Published Data

Product Dashboard—NeoCart

NovoCart 3D—US Timelines for Focal Cartilage Defects

NovoCart 3D—Europe Timelines for Focal Cartilage Defects

NovoCart 3D—Clinical Trial Design Approach and Key Published Data

NovoCart 3D—Clinical Trial Design Approach and Key Published Data (continued)

Product Dashboard—NovoCart 3D

RevaFlex—Timelines for Focal Cartilage Defects

RevaFlex—Clinical Trial Design Approach and Key Published Data

Product Dashboard—RevaFlex

Carticel—Clinical Trial Design Approach and Key Published Data

Carticel—Clinical Trial Design Approach and Key Published Data (continued)

Product Dashboard—Carticel

MACI—Clinical Trial Design Approach and Key Published Data

MACI—Clinical Trial Design Approach and Key Published Data (continued)

Product Dashboard—MACI

ChondroCelect—Clinical Trial Design Approach and Key Published Data

ChondroCelect—Clinical Trial Design Approach and Key Published Data (continued)

Product Dashboard—ChondroCelect

DeNovo NT—Clinical Trial Design Approach and Key Published Data

DeNovo NT—Clinical Trial Design Approach and Key Published Data (continued)

DeNovo NT—Clinical Trial Design Approach and Key Published Data (continued)

Product Dashboard—DeNovo NT

Product Dashboard—Cartiform

Product Dashboard—BioCartilage

Product Dashboard—Cartistem

Key Opinion Leader (KOL) Insights

Key Opinion Leader (KOL) Insights (continued)

Conclusions

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The standard of care, microfracture, does not fulfill long-term needs for patients with chondral defects. In addition, current alternative treatment options are plagued by multiple challenges and limitations. This research service focuses on medicine in the knee cartilage repair market, providing a detailed overview of 9 key products. A product and pipeline assessment is provided for marketed and investigational autologous cell-based therapy, allogenic cell-based therapy, and non-cellular products in the global, US, and European markets. Product profiles are included for companies that are currently or imminently marketing cell-based regenerative therapies and conducting clinical trials in the United States and Europe.
More Information
No Index No
Podcast No
Author Jennifer Lazar
WIP Number NE07-01-00-00-00
Is Prebook No